

**National Treatment Purchase Fund Board**

**Financial Statements**

**For Year Ended 31 December 2015**

## Table of Contents

	Page
Table of Contents	2
General Information	3
Statement of Board Members' Responsibilities	4
Statement of Internal Financial Control	5 - 7
Report of the Comptroller and Auditor General	8
Statement of Revenue Income and Expenditure and Retained Revenue Reserves	9
Statement of Financial Position	10
Statement of Cash Flows	11
Notes to the Financial Statements	12 - 25

## National Treatment Purchase Fund Board

### General Information

Board members :  
J Horan (Chairman)  
S Bailey (appointed 28/02/14)  
B Costello (appointed 28/02/14)  
P Gibbons (appointed 28/02/14)  
T McWade (appointed 28/02/14)  
J Melly (appointed 28/02/14)  
J Nagle (appointed 28/02/14)  
B O'Donoghue (appointed 28/02/14)  
A-M Taylor (appointed 28/02/14)

Board Secretary : L Lottering

Head Office: Ashford House  
Tara Street  
Dublin 2

Telephone No: +353 1 6427 101  
Fax No: +353 1 6427 102  
Website: [www.ntpf.ie](http://www.ntpf.ie)

Auditors: Comptroller and Auditor General  
3 Mayor Street Upper  
North Wall  
Dublin 1

Main Bankers: AIB Bank Limited  
Swords Road  
Santry  
Dublin 9

Solicitors: Philip Lee Solicitors  
7/8 Wilton Terrace  
Dublin 2

## National Treatment Purchase Fund Board

### Board Members' Report

For the year ended 31 December 2015

#### Statement of Board Members' Responsibilities

The Board is required by the National Treatment Purchase Fund Board (Establishment) Order 2004 to prepare financial statements for each financial year which give a true and fair view of the financial state of affairs of the NTPF Board and of its income and expenditure for the year reported.


In preparing these financial statements, the NTPF Board is required to:

- Select suitable accounting policies and apply them consistently
- Make judgements and estimates that are reasonable and prudent
- Disclose and explain any material departures from applicable accounting standards
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the Board will continue in operation.

The Board is responsible for keeping proper accounting records which disclose, with reasonable accuracy at any time, its financial position and enable it to ensure that the financial statements comply with accounting standards generally accepted in Ireland and comply with the National Treatment Purchase Fund Board (Establishment) Order 2004.

The Board is also responsible for safeguarding the assets of the organisation and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the NTPF Board:



J Horan

Chairperson

Date: 21 December 2016



T McWade

Board Member

Date: 21 December 2016

## National Treatment Purchase Fund Board

### **Statement of Internal Financial Control**

#### **Responsibility for the System of Internal Financial Control**

On behalf of the Board of the National Treatment Purchase Fund I acknowledge our responsibility for ensuring that an effective system of internal financial control is maintained and operated.

#### **Purpose of the System of Internal Control**

The system of internal financial control is designed to ensure that the National Treatment Purchase Fund Board is capable of responding to business risks and that significant control issues, should they arise, are escalated promptly to an appropriate level of management. A system of internal financial control is designed to reduce rather than eliminate risk. Such a system can provide only reasonable and not absolute assurance that assets are safeguarded, transactions are authorised and properly recorded and that material errors or irregularities are either prevented or detected in a timely manner.

It is confirmed that the system of internal control was in place for the whole of the financial year under review being the year ended 31 December 2015.

#### **Capacity to handle risk**

The following steps have been taken to ensure an appropriate control environment:

- The Board has a regular schedule of meetings at which it is provided with updated reports of expenditure trends and other financial planning and budgetary control issues.
- An Audit and Risk Committee has been established and operates under formal terms of reference that support a strong financial control environment. The Committee reports to the Board regularly.
- An Internal Audit Function operates in accordance with a written charter. Its work is informed by an analysis of the business risks to which the National Treatment Purchase Fund is exposed and its annual internal plans are based on this analysis. The internal audit function reports to the Audit and Risk Committee. Any instances of fraud or other irregularities that are identified are addressed by management and, where required, the appropriate authorities are notified.
- For the year under review, the Audit Committee, on behalf of the Board, arranged for Internal Audit to conduct a review of internal financial controls at the National Treatment Purchase Fund.

## National Treatment Purchase Fund Board

### Capacity to handle risk (cont.)

- Management responsibilities are clearly assigned, with corresponding accountability.
- Reporting procedures are well established at all levels where responsibility for financial management has been assigned.

### The Risk and Control Framework

The system of internal financial control is continually developed, maintained and monitored in response to the emerging requirements of the organisation. There is a framework of administration procedures and regular management reporting in place including segregation of duties and a system of delegation and accountability.

The following is an outline of key processes and procedures designed to provide effective internal financial control, which are in place across the organisation:

- The Board is currently drafting a Corporate Plan having recently received clarification from the Department of Health as to a medium term role. The plan will set out the Board's objectives over a 3 year period with appropriate targets and key performance measures being identified. The Corporate Plan will be formulated after taking account of the views of the Board members, management, staff, service users and understanding external factors such as government policy and stakeholders needs. Performance against the Corporate Plan will be reported in the Annual Report at the end of each financial year.
- There is an appropriate budgeting system with an annual budget which is kept under review by senior management.
- There are regular reviews by senior management of periodic and annual financial reports which indicate financial performance against forecast.
- A risk management system operates within the National Treatment Purchase Fund Board. Formal procedures have been established for reporting significant control failures and ensuring appropriate corrective action.
- There are systems aimed at ensuring the security of the ICT systems.
- The National Treatment Purchase Fund is compliant with all pay and travel circulars issued by Department of Public Expenditure and Reform and all relevant guidelines regarding procurement.

## National Treatment Purchase Fund Board

### Review of Effectiveness


The Board has responsibility for reviewing the effectiveness of the system of internal control and can confirm that this was conducted for the Year Ending December 2015.

The review was informed by:

- The executive managers within the organisation who have responsibility for the development and maintenance of the internal control framework;
- The work of the internal auditors, who submit to the National Treatment Purchase Fund reports which include an objective opinion on the adequacy and effectiveness of the organisation's systems of internal control together with recommendations for improvement;
- Comments made by the Office of the Comptroller & Auditor General in their management letter.

### Significant Internal Control Issues

In 2015 there have been no significant breaches of the control environment of the National Treatment Purchase Fund Board, but, whilst no material breaches have been identified there is a need for continued emphasis on, and the development of, the control environment.



J Horan  
Chairperson  
Date: 21 December 2016







## Comptroller and Auditor General

### Report for presentation to the Houses of the Oireachtas

---

#### National Treatment Purchase Fund Board

I have audited the financial statements of the National Treatment Purchase Fund Board for the year ended 31 December 2015 under Section 5 of the Comptroller and Auditor General (Amendment) Act 1993. The financial statements comprise the statement of revenue income and expenditure and retained revenue reserves, the statement of financial position, the statement of cash flows and the related notes. The financial statements have been prepared in the form prescribed under Section 10 of SI Number 179/2004 National Treatment Purchase Fund Board (Establishment) Order 2004, and in accordance with generally accepted accounting practice as modified by the Minister for Health in relation to accounting for superannuation costs.

#### Responsibilities of the members of the Board

The Board is responsible for the preparation of the financial statements, for ensuring that they give a true and fair view of the state of affairs of the National Treatment Purchase Fund Board and for ensuring the regularity of transactions.

#### Responsibilities of the Comptroller and Auditor General

My responsibility is to audit the financial statements and report on them in accordance with applicable law.

My audit is conducted by reference to the special considerations which attach to State bodies in relation to their management and operation.

My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) and in compliance with the Auditing Practices Board's Ethical Standards for Auditors.

#### Scope of audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements, sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of

- whether the accounting policies are appropriate to the Board's circumstances, and have been consistently applied and adequately disclosed
- the reasonableness of significant accounting estimates made in the preparation of the financial statements, and
- the overall presentation of the financial statements.

I also seek to obtain evidence about the regularity of financial transactions in the course of audit.

#### Opinion on the financial statements

In compliance with the directions of the Minister for Health, the Board accounts for the costs of superannuation entitlements only as they become payable. This basis of accounting does not comply with Financial Reporting Standard 102 which requires such costs to be recognised in the year the entitlements are earned.

In my opinion, except for the accounting treatment of the Board's superannuation costs and liabilities, the financial statements,

- give a true and fair view of the assets, liabilities and financial position of the National Treatment Purchase Fund Board as at 31 December 2015 and of its income and expenditure for 2015; and
- have been properly prepared in accordance with generally accepted accounting practice.

In my opinion, the accounting records of the National Treatment Purchase Fund Board were sufficient to permit the financial statements to be readily and properly audited. The financial statements are in agreement with the accounting records.

#### Matters on which I report by exception

I report by exception if I have not received all the information and explanations I required for my audit, or if I find

- any material instance where money has not been applied for the purposes intended or where the transactions did not conform to the authorities governing them, or
- the statement on internal financial control does not reflect the Board's compliance with the Code of Practice for the Governance of State Bodies, or
- there are other material matters relating to the manner in which public business has been conducted.

I have nothing to report in regard to those matters upon which reporting is by exception.

**Seamus McCarthy**  
Comptroller and Auditor General

23 December 2016



## National Treatment Purchase Fund Board

### Statement of Revenue Income and Expenditure and Retained Revenue Reserves


For the year ended 31 December 2015

	Notes	2015 €	2014 Re-stated €
<b>Income</b>			
Oireachtas Grants	2	5,100,000	5,100,000
HSE Income	3	20,354,016	-
Other Income	4	90,382	115,008
<b>Total Income</b>		<b>25,544,398</b>	<b>5,215,008</b>
<b>Less: Expenditure</b>			
Patient Care Expenditure	6	21,345,689	484,193
Administration Expenses	5	1,230,435	1,861,488
Salaries and Remuneration	7	2,040,896	2,596,046
<b>Total Expenditure</b>		<b>24,617,020</b>	<b>4,941,727</b>
<b>Surplus for the Year before Appropriations</b>		<b>927,378</b>	<b>273,281</b>
<b>Transfer from / (to) Capital Account</b>	13	<b>44,754</b>	<b>(30,685)</b>
<b>Surplus for the Year after Appropriations</b>		<b>972,132</b>	<b>242,596</b>
Balance Brought Forward at 1 January		182,121	(60,475)
<b>Balance Carried Forward at 31 December</b>		<b>1,154,253</b>	<b>182,121</b>

All income and expenditure for the year relates to continuing activities at the reporting date. The Statement of Revenue Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the year.

The Statement of Cash Flows and notes 1 to 17 form part of these financial statements

On Behalf of the National Treatment Purchase Fund Board:



J Horan

Chairperson

Date: 21 December 2016



T McWade

Board Member

Date: 21 December 2016


## National Treatment Purchase Fund Board

### Statement of Financial Position as at 31 December 2015

	Notes	2015 €	2014 Re-stated €
<b>Fixed Assets</b>	8	125,278	170,032
<b>Current Assets</b>			
Receivables and Prepayments	9	12,668,104	195,361
Cash at Bank and Cash in Hand	10	2,123,481	1,662,394
		<u>14,791,585</u>	<u>1,857,755</u>
<b>Current Liabilities (amounts falling due within one year)</b>			
Care Payables and Accruals	11	13,456,964	729,536
Non-Care Payables and Accruals	12	180,368	946,098
		<u>13,637,332</u>	<u>1,675,634</u>
<b>Net Current Assets</b>		<u>1,154,253</u>	<u>182,121</u>
<b>Total Net Assets</b>		<u>1,279,531</u>	<u>352,153</u>
<b>Representing</b>			
Revenue Income and Expenditure Account		1,154,253	182,121
Capital Account	13	125,278	170,032
		<u>1,279,531</u>	<u>352,153</u>

The Statement of Cash Flows and notes 1 to 17 form part of these financial statements

On Behalf of the National Treatment Purchase Fund Board:

  
 J Horan  
 Chairperson  
 Date: 21 December 2016

  
 T McWade  
 Board Member  
 Date: 21 December 2016

## National Treatment Purchase Fund Board

### Statement of Cash Flows For the year ended 31 December 2015

		2015	2014
	Note	€	Re-stated €
<b>Net Cash Flow from Operating Activities</b>			
Excess Income over Expenditure		927,378	273,281
Depreciation and impairment of fixed assets	8	60,495	80,261
(Increase) in receivables		(12,472,742)	(96,829)
Increase in payables		11,961,698	1,057,375
<b>Net Cash Inflow from Operating Activities</b>		<b>476,829</b>	<b>1,314,088</b>
<b>Cash Flows from Investing Activities</b>			
Payments to acquire property, plant and equipment	8	(15,742)	(110,946)
<b>Net Cash Flows from Investing Activities</b>		<b>(15,742)</b>	<b>(110,946)</b>
<b>Cash Flows from Financing Activities</b>			
Bank interest received		-	-
Bank interest paid		-	-
<b>Net Cash Flows from Financing Activities</b>		<b>-</b>	<b>-</b>
<b>Net Increase in Cash and Cash Equivalents</b>		<b>461,087</b>	<b>1,203,142</b>
Cash and Cash Equivalents at 1 January		1,662,394	459,252
Cash and Cash Equivalents at 31 December		2,123,481	1,662,394

## National Treatment Purchase Fund Board

Notes to the financial statements  
For the year ended 31 December 2015

### 1. Accounting Policies

The basis of accounting and significant accounting policies adopted by the National Treatment Purchase Fund Board (NTPF Board) are set out below. They have all been applied consistently throughout the year and for the preceding year.

#### a) General Information

The NTPF Board was set up under the National Treatment Purchase Fund Board (Establishment) Order 2004 with a head office at Ashford House, Tara Street, Dublin 2.

The NTPF Board's primary objectives are as follows;

- (i) To make arrangements with persons, whether resident in the State or elsewhere, for the provision of hospital treatment to such classes of persons as may be determined by the Minister from time to time.
- (ii) To collect, collate and validate information in relation to persons waiting for hospital treatment and to put in place information systems and procedures for that purpose.
- (iii) To furnish whenever so required by the Minister or on its own initiative, advice to the Minister on issues relating to its functions.
- (iv) To negotiate with proprietors of registered nursing homes to reach agreement in relation to the maximum prices(s) that will be charged for the provision of long-term residential care services to Nursing Homes Support Scheme Residents and provide the HSE with the details of all approved Nursing Homes agreements.
- (v) To develop and implement schemes to support and facilitate the gradual reduction in maximum outpatient first appointment waiting times.
- (vi) To support measures to facilitate improved patient experience time and performance in hospital emergency departments through targeted programmes of support.

In May 2015, the Health Service Executive (HSE) tendered for private hospitals to provide inpatient and outpatient services to all patients on waiting lists for in excess of 18 months. Individual hospitals were selected to provide specified procedures/treatments at agreed rates. The HSE arranges for treatment to be delivered to patients on its waiting lists. NTPF provided some administrative support to this initiative by way of disbursing payments to the private hospitals.

## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### **a) General Information (cont.)**

The future role and scope of the NTPF Board is being re-considered in the context of the overall reform of the health services. A process is underway between the NTPF Board and the Minister for Health and his officials as to how the reform will affect the NTPF Board. In keeping with that process of change funds are being made available to the NTPF Board during 2017 to facilitate the treatment of public patients.

The NTPF Board is a Public Benefit Entity (PBE)

### **b) Statement of Compliance**

The financial statements of the NTPF Board for the year ended 31 December 2015 have been prepared in accordance with FRS 102, the financial reporting standard applicable in the UK and Ireland issued by the Financial Reporting Council (FRC), as promulgated by Chartered Accountants Ireland. These are NTPF Board's first set of financial statements prepared in accordance with FRS 102. The date of transition to FRS 102 is 1 January 2014. The prior year financial statements have been re-stated for material adjustments on adoption of FRS 102 in the current year. The result of this adoption can be seen in Note 16.

The NTPF has adopted FRS 102 in accordance with accounting standards issued by the Financial Reporting Council, except that pensions are accounted for on a pay-as-you-go basis. The provisions of FRS 102 Section 28 Employee Benefits are not applied and the liability for future pension benefits accrued in the year has not been recognised in the financial statements.

### **c) Basis of Preparation**

The financial statements have been prepared under the historical cost convention, except for certain assets and liabilities that are measured at fair value as explained in the accounting policies below.

The financial statements are in the form approved by the Minister for Health with the concurrence of the Minister for Finance under the National Treatment Purchase Fund Board (Establishment) Order 2004.

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to NTPF Board's financial statements.

## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### **d) Revenue**

#### Oireachtas Grants

Revenue is generally recognised on an accruals basis. However, Oireachtas Grants are provided to meet liabilities maturing during the year as opposed to expenses incurred during the year and are accounted for on a cash receipts basis.

#### Health Service Executive Income

Income from the Health Service Executive is recognised in the year in which the medical care is provided.

#### Other Revenue

Other revenue is recognised on a cash receipts basis.

### **e) Patient care expenditure**

Care expenditure is recognised in the year in which the medical care is provided.

### **f) Property, Plant and Equipment**

Property, plant and equipment are stated at cost less accumulated depreciation, adjusted for any provision for impairment. Depreciation is provided on all property, plant and equipment on a straight line basis at rates which are estimated to reduce the assets to residual values by the end of their expected useful lives as follows:

Computer Software and Equipment	20% per annum
Office Equipment	20% per annum
Furniture and Fittings	10% per annum

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of an age and in the condition expected at the end of its useful life.



## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### **f) Property, Plant and Equipment (cont.)**

Expenditure incurred on the development of computer systems, which is substantial in amount, and is considered to have an economic benefit to the Board lasting more than one year into the future is capitalised and depreciated over the period in which the economic benefits are expected to arise. This period is subject to a maximum of 5 years. In the event of uncertainty regarding its future economic benefit an impairment loss is recognised in the Statement of Revenue Income and Expenditure and Retained Revenue Reserves in the year.

### **g) Inventory**

As the Board does not carry any material inventory all unused sundry consumable items (e.g. stationery, printed material etc.) are charged in full to the Statement of Revenue Income and Expenditure and Retained Revenue Reserves in the period in which they were first acquired.

### **h) Receivables**

Receivables are recognised at fair value, less provision for doubtful debts. The provision for doubtful debts is a specific provision, and is established when there is objective evidence that the NTPF Board will not be able to collect all amounts owed to it. All movements in the provision for doubtful debts are recognised in the Statement of Revenue Income and Expenditure and Retained Revenue Reserves.

### **i) Operating Leases**

Rental expenditure under operating leases is recognised in the Statement of Revenue Income and Expenditure and Retained Revenue Reserves over the life of the lease. Expenditure is recognised on a straight line basis over the lease period.

### **j) Employee Benefits**

#### Short-term Benefits

Short term benefits such as holiday pay are recognised as an expense in the year, and benefits that are accrued at year-end are included in the Payables figure in the Statement of Financial Position.

#### Retirement Benefits

Pension entitlements of employees directly employed by the Board are provided for through a defined benefit scheme currently being finalised with the Departments of Health and Public Expenditure & Reform. Funding is provided when pension payments

## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### **j) Employee Benefits (cont.)**

are made. Pension contributions deducted from employees' salaries are recognised as income in the Statement of Revenue Income and Expenditure and Retained Revenue Reserves. Pension payments are charged to the Statement of Revenue Income and Expenditure and Retained Revenue Reserves when paid. No provision is made in the financial statements in respect of future pension benefits. To date, no formal actuarial valuations of the NTPF Board's pension liabilities has been carried out.

Pension benefits of staff seconded to the NTPF Board remain the responsibility of their parent bodies. The employer cost of providing these benefits is charged to the Statement of Revenue Income and Expenditure and Retained Revenue Reserves and is remitted to the parent bodies together with the relevant employee contributions.

### **k) Capital account**

The capital account represents the unamortised value of income applied to capital expenditure. Releases are made from this reserve to the Income and Expenditure and Retained Revenue Reserves in line with the depreciation and write-down of the assets.

### **l) Foreign Transactions**

Foreign transactions during the period have been translated at the rate of exchange ruling at the date of the transaction.

### **m) Critical Accounting Judgements and Estimates**

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. The nature of estimation means that actual outcomes could differ from those estimates. However, there were no judgements required that had a significant effect on amounts recognised in the financial statements for 2015.

#### Depreciation and Residual Values

The NTPF Board have reviewed the asset lives and associated residual values of all fixed asset classes, and in particular, the useful economic life and residual values of fixtures and fittings, and have concluded that asset lives and residual values are appropriate.

## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### 2 Oireachtas Grants

The Oireachtas Grants voted to National Treatment Purchase Fund Board from Vote 38 Health as shown in the financial statements consist of;

		<b>2015</b>	<b>2014</b>
		€	€
Grants for current expenditure	<b>Sub-head E3</b>	5,100,000	5,100,000

		<b>2015</b>	<b>2014</b>
		€	€
<b>3 HSE Income</b>		€	€
NTPF/HSE Outsourcing initiative		20,354,016	-

During 2015 NTPF provided administrative support to a special HSE initiative whereby longest waiting public patients were treated in private hospitals. This support concerned disbursing payments to the participating private hospitals. Patient care expenditure of €20.35m in respect of 2015 was processed in this way by NTPF

		<b>2015</b>	<b>2014</b>
		€	€
<b>4 Other Income</b>		€	€
Superannuation contributions		90,382	96,561
Other Sundry Income		-	18,447
		<u>90,382</u>	<u>115,008</u>

## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

	2015	2014
		Re-stated
5 Administration Expenses	€	€
Office rent	442,897	442,897
Computer expenses	306,259	260,337
Office expenses	151,048	696,914
Transport and Travel	68,258	61,422
Professional services	61,624	105,503
Depreciation	60,495	80,261
Legal fees	53,930	100,855
Training and Recruitment	25,221	51,047
Premises cleaning and maintenance	20,553	26,041
Insurance	10,158	8,540
Board expenses	10,068	9,026
Advertising and Promotion	8,795	0
Audit fees	8,500	15,000
Miscellaneous costs	2,089	3,116
Bank charges	540	530
	1,230,435	1,861,488
	1,230,435	1,861,488

The costs of administering NTPF's role under the Nursing Homes Support Scheme Act are included in salaries and overheads. These costs amount to €299,173 (2014 €327,405).

Office expenses for 2014 includes a charge of €621,402 in respect of service charges, agreed in 2015, for NTPF's premises at Ashford House covering the period 2004 to 2014.

Professional services for 2014 includes a settlement payment of €39,323 agreed between NTPF and a consultant arising from the termination of a contract for services.

#### 6 Patient Care Expenditure

In 2015 the majority of expenditure incurred by NTPF related to payments to private hospitals to provide inpatient and outpatient services to patients who had been on waiting lists for in excess of 18 months as at June 2015. The expenditure is broken down by payee and speciality overleaf.

## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

#### 6 Patient Care Expenditure (cont.)

	2015	2014
6 (a) Patient Care Expenditure by payee	€	€
Private Hospitals	21,330,689	-
HSE	-	484,193
Voluntary Hospitals	15,000	-
	<u>21,345,689</u>	<u>484,193</u>

	2015	2014
6 (b) Patient Care Expenditure by speciality	€	€
Orthopaedics	5,509,381	-
ENT	3,794,944	-
General Surgery	2,689,430	484,193
Urology	2,473,238	-
Neurosurgery	1,378,357	-
Cardiac Surgery/ Cardiology	1,537,431	-
Ophthalmology	992,493	-
Non-cosmetic Plastic Surgery	977,058	-
Radiology	770,633	-
Vascular Surgery	561,278	-
Gynaecology	430,835	-
Dental and Oral Surgery	110,575	-
Surgical Dermatology	45,944	-
Rheumatology	42,281	-
Neurology	30,914	-
Pain Management	757	-
Endocrinology	141	-
Total	<u>21,345,689</u>	<u>484,193</u>

## National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

### 7 Remuneration and Pay Costs

	2015	2014
7(a) Salaries and Pensions	€	Re-stated €
<b>Staff Salaries :</b>		
Management	259,195	292,871
Administration	1,711,515	2,232,549
Board Fees	70,186	70,627
<b>Total Payroll Cost</b>	<u>2,040,896</u>	<u>2,596,046</u>

Pension levy deductions of €118,875 (2014 €127,470) were made from staff salaries and remitted to the Department of Health.

Pending consideration of NTPF's role, 6 employees were temporarily seconded to other Health Agencies during 2015. Salary costs relating to these staff are being recouped from the Agencies in question. A further 12 employees, with a salary cost of €436,764 (2014 €588,581) were similarly assigned to other Health Agencies without salary recoupment to the Board.

	2015	2014
Average Number of Employees during the year	45	47
Of which were seconded	-18	-25
	€	€
7(b) Chief Executive's Salary	-	-

The Chief Executive Officer (CEO) was appointed on an acting basis with effect from 28 May 2014. In addition to the role and duties as Acting CEO in the NTPF, the CEO also carries out a role in the Office of the Director General of the HSE. His annual salary from the HSE is €102,314. The Acting CEO did not receive any extra remuneration for additional duties with the NTPF.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.)  
For the year ended 31 December 2015

7(c) Employee benefits breakdown		Number of Employees	
From	To	2015	2014
€60,000	- €69,999	4	3
€70,000	- €79,999	2	2
€80,000	- €89,999	-	-
€90,000	- €99,999	-	-
€100,000	- €109,999	1	1
<b>Total</b>		<b>7</b>	<b>6</b>

7(d) Board Members' Emoluments

Board Member	Board Fees €	PRSI on Board Fees €	Vouched Expenses €	Meetings attended		
				Board (9)	Audit & Risk Committee (6)	Strategy Committee (6)
J Horan (Chair)	11,970	0	932	9		
S Bailey	7,695	654	1,148	7		2
P Gibbons	7,695	654	201	9	6	
T McWade	7,695	654		9	6	
J Melly	7,695	0	355	9		6
J Nagle	7,695	654	4,219	8		6
B O'Donoghue	7,695	654		9	5	
A-M Taylor	7,695	654		8		5
M Barron (advisor)	424	2		0	1	
B Costello	0	0	3,212	9	6	
<b>Total</b>	<b>66,259</b>	<b>3,927</b>	<b>10,068</b>			

## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

#### 8 Property, Plant & Equipment

	Computer Equipment and Software	Office Equipment	Furniture, Fixtures and Fittings	Total
Depreciation Rate	20%	20%	10%	
	€	€	€	€
<b>Cost</b>				
At 1 January 2015	4,777,458	151,585	386,434	5,315,478
Additions	9,919	5,823	-	15,742
Disposals	(40,852)	-	-	(40,852)
At 31 December 2015	<b>4,746,525</b>	<b>157,408</b>	<b>386,434</b>	<b>5,290,367</b>
<b>Depreciation</b>				
At 1 January 2015	(4,618,436)	(147,202)	(379,807)	(5,145,446)
Charge for the Year	(54,653)	(3,499)	(2,343)	(60,495)
Disposals	40,852	-	-	40,852
At 31 December 2015	<b>(4,632,238)</b>	<b>(150,701)</b>	<b>(382,151)</b>	<b>(5,165,089)</b>
<b>Net Book Value</b>				
At 1 January 2015	159,022	4,383	6,627	170,032
Net movement for the year	(44,734)	2,324	(2,343)	(44,754)
At 31 December 2015	<b>114,288</b>	<b>6,707</b>	<b>4,284</b>	<b>125,278</b>

	2015 €	2014 €
<b>9 Receivables and prepayments</b>		
Health Services Executive	12,650,614	-
Other Sundry Receivables	6,275	10,891
Prepayments	11,215	184,470
	<b>12,668,104</b>	<b>195,361</b>



## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

<b>10 Cash at Bank and in Hand</b>	<b>2015</b>	<b>2014</b>
	€	€
Bank Current Account	2,123,181	1,662,094
Petty Cash	300	300
	<u>2,123,481</u>	<u>1,662,394</u>
	<b>2015</b>	<b>2014</b>
<b>11 Care Payables and Accruals</b>	€	€
Care payables	142,047	220,796
Care accruals	13,314,917	508,740
	<u>13,456,964</u>	<u>729,536</u>
	<b>2015</b>	<b>2014</b>
<b>12 Non-Care Payables and Accruals</b>	€	Re-stated €
Professional Services Withholding Tax	35,431	977
PAYE / PRSI and Government Levies	64,430	(3,962)
Other non care payables and accruals	80,507	949,082
	<u>180,368</u>	<u>946,098</u>
	<b>2015</b>	<b>2014</b>
<b>13 Capital Account</b>	€	€
Balance at 1 January	170,032	139,347
Funds allocated to acquire fixed assets	15,742	110,946
Amortisation in line with asset depreciation	(60,495)	(80,261)
Balance at 31 December	<u>125,278</u>	<u>170,032</u>

## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

#### 14 Operating Leases

The National Treatment Purchase Fund occupies premises at Ashford House, Tara Street, Dublin 2 under a lease agreement commencing 17 September 2009 and expiring on 16 June 2014. It was agreed to extend the terms and conditions of this lease to 31 December 2015. A further extension has been agreed to 31 December 2016.

<b>Operating lease rentals (charged to Revenue Income and Expenditure and Retained Reserves)</b>	<b>2015</b>	<b>2014</b>
	<b>€</b>	<b>€</b>
Land and Buildings	442,897	442,897

#### **The Board has the following commitments under operating leases which expire**

Within 1 year	442,897	442,897
Within 2 to 5 years	-	-

Operating lease payments recognised as an expense were €442,897 (2014 €442,897)

#### 15 Related Party Disclosures

Key management personnel of the NTPF Board consist of members of the Board, the CEO and Senior Managers. Total compensation paid to key management personnel, including Board member's fees and expenses amounted to €339,449 (2014 €368,338). For a breakdown of the remuneration and benefits paid to key management personnel see Note 7.

The NTPF Board adopts procedures in accordance with the guidelines issued by the Department of Public Expenditure and Reform covering the personal interests of Board members. In the normal course of business the NTPF Board may enter into contractual arrangements with entities in which the NTPF Board members are employed or are otherwise interested.

During the year the NTPF Board had no dealings with any bodies connected to any of the Board members.

## National Treatment Purchase Fund Board

### Notes to the financial statements (cont.) For the year ended 31 December 2015

#### 16 Transition to FRS 102

<b>Reconciliation of Capital and Reserves</b>	<b>As at 01-Jan-14 €</b>	<b>As at 31-Dec-14 €</b>
Capital and Reserves (as previously stated)	124,818	386,684
Holiday pay accrual	(45,947)	(34,531)
Capital and Reserves (as re-stated)	<u>78,871</u>	<u>352,153</u>
		Year ended <b>31-Dec-14</b> €
Reconciliation of Surplus for the year		
Surplus for the year (as previously stated)		231,180
Holiday pay accrual adjustment		<u>11,416</u>
Surplus for the year (as re-stated)		<u>242,596</u>

#### Adjusting items

The NTPF Board had previously not accrued for holiday pay earned by employees but not availed of at the reporting date. Under FRS 102, the financial statements must recognise such accruals.

The impact of this change is an increase of €45,947 in creditors at the transition date and €34,531 at 31 December 2014. The surplus is reduced by €45,947 in the year ended 31 December 2013 and increased by €11,416 in the year ended 31 December 2014.

As FRS 102 does not allow for a separate Capital Income & Expenditure account a technical adjustment has been made to reflect this.

#### 17 Approval of the financial statements

The financial statements were approved by the National Treatment Purchase Fund Board on 12 December 2016.

